



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/465,322	06/05/1995	HANS E. SODERLUND	A28203-A-FWC	1828

7590

04/25/2002

KALOW, SPRINGUT & BRESSLER, LLP
488 MADISON AVENUE
19TH FLOOR
NEW YORK, NY 10022

EXAMINER

MYERS, CARLA J

ART UNIT

PAPER NUMBER

1634

DATE MAILED: 04/25/2002

36

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

08/465,322

Applicant(s)

SODERLUND ET AL.

Examiner

Carla J. Myers

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 05 April 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 51-53, 56, 57, 59, 62, 63 and 67 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 51-53, 56, 57, 59, 62, 63 and 67 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

Art Unit: 1634

1. The request filed on April 5, 2002 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 08/465,322 is acceptable and a CPA has been established. An action on the CPA follows. All rejections not reiterated herein are hereby withdrawn.

2. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(f) or (g) prior art under 35 U.S.C. 103(a).

Claims 51-53, 63, 67, 71-75 are rejected under 35 U.S.C. § 103 as being unpatentable over Erlich (U.S. Patent No. 5,310,893) in view of Mullis (U.S. Patent No. 4,683,202; cited in the IDS of Paper No. 5).

Erlich (see, for example, col. 8) teaches primers useful for the amplification of target nucleic acids containing a variable nucleotide, such as a polymorphism/mutation. In particular, Erlich teaches primer "DB01" (see columns 29 and 30), which hybridizes to the target nucleic acid so that the 3' nucleotide of the primer is immediately adjacent to a variable nucleotide and extension of the primer results in the addition of a nucleotide complementary to a first or second

Art Unit: 1634

nucleotide residue. It is pointed out that the 3' residue of the DB01 primer flanks the "CTT" codon, which is present as a "GTG" codon in allelic variants and thereby the "C" nucleotide adjacent to the primer is considered to be a variable or mutated nucleotide and the "C" and "G" nucleotides are considered to be a first and a second "nucleic acid residue at a defined site".

Erich teaches that primers may be 15 to 25 nucleotides in length (col. 4) and teaches that the DB01 primer is 21 nucleotides in length (col. 29). Erlich also teaches that, following the amplification reaction, the sequence of sample nucleic acids can be determined and confirmed by dideoxy chain termination sequencing. It is conventional in the field of dideoxy chain termination sequencing to use labeled dideoxynucleotide triphosphates to facilitate detection of the sequencing products. Erlich further teaches that the amplification reaction is performed using dNTPS and a polymerase. It is stated that the amplification may be performed using labeled reagents in order to allow for the detection of the amplification products and Erlich exemplifies methods in which the primers are labeled with detectable moieties (see, for example, col. 5). Erlich does not exemplify methods using labeled dNTPS.

However, Mullis (col. 14) teaches that in PCR either the primer or the dNTPS may contain detectable moieties. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the method of Erlich so as to have amplified the target nucleic acids using labeled dNTPs in place of labeled primers in order to have provided an equally effective means for facilitating detection of the amplification products. Such a modification of the method of Erlich would have resulted in a method which comprised the use of the reagents of a target nucleic acid, a DB01 oligonucleotide primer consisting of a

Art Unit: 1634

sequence that hybridizes to the target nucleic acid immediately adjacent to a variable nucleotide position, labeled nucleotides and/or labeled dideoxynucleotide triphosphates, and a polymerase.

Erlich does not specifically disclose a kit comprising each of these reagents. However, Erlich (col 26) does suggest that kits should be prepared containing all of the reagents required to practice the disclosed amplification technique wherein such kits comprise, for example, a primer, the substrate nucleoside triphosphates, means used to label, and an agent used to catalyze primer extension. Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have generated a kit for practicing the method of Erlich which contained the reagents of target nucleic acid, the DB01 amplification primer, labeled nucleotides or labeled dideoxynucleotides and a polymerase in order to have achieved the expected benefits of convenience and cost-effectiveness for practitioners of the art. With respect to claims 63 and 67, Erlich does not specifically exemplify a DB01 primer having attached thereto an "attachment moiety" through which the primer can be immobilized or immobilization of the primer and the amplification product onto a solid support. However, Erlich does teach that primers useful for amplifying variable nucleotides can be modified so as to attach labels thereto, including labels which can be used to capture the primer and facilitate immobilization of the primer onto a solid support (see col. 5). Accordingly, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the amplification primer of Erlich so as to have attached an affinity moiety to the primer to allow for the immobilization of the primer in order to have accomplished the expected advantage of generating a primer which could easily be

Art Unit: 1634

immobilized onto a solid support to have allowed for the rapid and efficient separation and isolation of the nucleic acids comprising the amplification primer from other nucleic acids.

3. Claims 51, 53, 72-75 are rejected under 35 U.S.C. 103(a) as being unpatentable over Mundy (U.S. Patent No. 4,656,127; cited in IDS of Paper NO. 5).

Mundy et al disclose methods for detecting a target nucleic acid wherein the methods comprise hybridizing a primer to a target nucleic acid so that the primer terminates immediately upstream of a variable nucleotide; extending the primer using a polymerizing agent and a chain terminating reagent, wherein the primer is extended if the chain terminating agent is the complement of the variable nucleotide; admixing the resulting product with one or more labeled nucleotides, so that the primer is extended to incorporate the nucleotides, if the chain terminating agent is not already linked to the primer (see column 3). Mundy teaches that the chain terminating reagent may be a dideoxynucleotide, and that different dideoxynucleotides are employed depending on the variable nucleotide to be detected. The reference also teaches that the nucleotide derivatives may be labeled (see column 6) and are at least 10 nucleotides in length (column 5). Primers may also be employed which do not terminate immediately adjacent to the variable nucleotide, in which case one or more nucleotides (dATP, dCTP, dGTP and/or dTTP) are included in the chain terminating reaction (see for example claim 7). The target nucleic acid may be bound to a solid support such that the resulting primer extension product is immobilized onto a solid support (see column 4). Accordingly, the method of Mundy requires the use of a primer which hybridizes upstream of a variable nucleotide to be detected, a polymerizing reagent, labeled nucleotides, and chain terminating reagents. Mundy does not teach packaging

Art Unit: 1634

the reagents required to practice the detection method in a kit. However, reagent kits for performing diagnostic methods were conventional in the field of molecular biology at the time the invention was made. Therefore, it would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have packaged the primer, polymerizing agent, dideoxynucleotides and labeled nucleotides in a kit for the expected benefits of convenience and cost-effectiveness for practitioners in the art wishing to detect mutations in target nucleic acids.

4. Claims 56-57 are rejected under 35 U.S.C. § 103 as being unpatentable over Mundy in view of Emi (Genomics (1988) 3:373-379).

The teachings of Mundy are presented above. In particular, Mundy teaches that the primer comprises sequences complementary to the target nucleic acid and that the primer terminates immediately 3' to the predetermined nucleotide position. It is stated that the detection method can be used to detect nucleotide variation in any target gene, including the beta-globin gene and ras oncogene (col. 1-2). However, Mundy does not specifically teach primers for detecting mutations in the ApoE gene. Emi teaches allele specific probes for detecting mutations in the apoE gene. Furthermore, at the time the invention was made the complete sequence of the apoE gene was known. In view of the teachings of Mundy of how to select primers for detecting nucleotide variation and in view of the teachings of Emi of the specific mutations in the apoE gene and the disclosure of allele specific probes for detecting these mutations, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have generated primers comprising sequences complementary to the apoE

Art Unit: 1634

gene immediately flanking the modified nucleotide encoding codons 112 and 158 and thereby to have generated primers comprising sequences identical to those of the instantly claimed primers in order to have provided primers and kits comprising said primers useful for the detection of sequence variation in the apoE gene.

5. Claim 59 is rejected under 35 U.S.C. § 103 as being unpatentable over Mundy in view of Saiki (Nature (1986) 324:163-166).

The teachings of Mundy are presented above. In particular, Mundy teaches that the primer comprises sequences complementary to the target nucleic acid and that the primer terminates immediately 3' to the predetermined nucleotide position. It is stated that the detection method can be used to detect nucleotide variation in any target gene (see columns 1-2). However, Mundy does not exemplify primers for detecting mutations in the beta-globin gene. Saiki teaches allele specific probes for detecting mutations (A to T) in codon 6 of the beta-globin gene. Furthermore, at the time the invention was made the complete sequence of the beta-globin gene was known. In view of the teachings of Mundy of how to select primers for detecting nucleotide variation and in view of the teachings of Saiki of the specific mutation in the beta globin gene leading to sickle cell anemia and the disclosure of allele specific probes for detecting this mutation, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have generated primers comprising sequences complementary to the beta-globin gene immediately flanking the modified nucleotide encoding codon 6 and thereby to have generated primers comprising sequences identical to those of the instantly claimed primers

Art Unit: 1634

in order to have provided primers and kits comprising said primers useful for the detection of the sickle cell mutation.

8. Claim 62 is rejected under 35 U.S.C. § 103 as being unpatentable over Mundy in view of Farr et al (PNAS (1988) 85:1629-1633; cited on IDS of Paper No. 5).

The teachings of Mundy are presented above. In particular, Mundy teaches that the primer comprises sequences complementary to the target nucleic acid and that the primer terminates immediately 3' to the predetermined nucleotide position. It is stated that the detection method can be used to detect nucleotide variation in any target gene (columns 1-2). However, Mundy does not exemplify primers for detecting mutations in the ras oncogene. Farr teaches allele specific probes for detecting mutations in codon 12 of the ras oncogene (see Table 1). Furthermore, at the time the invention was made the complete sequence of the ras oncogene was known. In view of the teachings of Mundy of how to select primers for detecting nucleotide variation and in view of the teachings of Farr of the specific mutations in the ras oncogene and the disclosure of allele specific probes for detecting these mutations, it would have been obvious to one of ordinary skill in the art at the time the invention was made to have generated primers of about 18 nucleotides comprising sequences complementary to the ras oncogene immediately flanking the modified nucleotide encoding codon 12 and thereby to have generated primers comprising sequences identical to those of the instantly claimed primers in order to have provided primers and kits comprising said primers useful for the detection of genetic variation in the ras oncogene.

Serial Number: 08/465,322

-9-

Art Unit: 1634


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Carla Myers whose telephone number is (703) 308-2199. The examiner can normally be reached on Monday-Thursday from 6:30 AM-5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W. Gary Jones, can be reached on (703)-308-1152. The fax number for the Technology Center is (703)-305-3014 or (703)-305-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to the receptionist whose telephone number is (703) 308-0196.

Carla Myers

April 22, 2002


CARLA J. MYERS
PRIMARY EXAMINER